Caleco Pharma Corp. (OTCBB: CAEH) recently announced that it has retained Rearden Health Partners, a healthcare media and communications firm that specializes in healthcare product development. This alliance will allow Rearden Health Partners to directly participate in the management of Caleco Pharma's product licensing, research & development and commercialization activities. In addition, several members of the Rearden Health Partners team will assume executive level roles of Caleco Pharma, participating in general corporate management activities.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
The senior members of the Rearden team that will work with Caleco each have over 20 years experience in healthcare product development and commercialization and have worked on the launch of over 100 prescription and OTC products since 1975. "The alliance of Rearden Health Partners and Caleco Pharma will use proprietary communications products, services and strategies with the goal of increasing the value of Caleco's growing product pipeline and bringing innovative products to market. The approaches we bring to pre-commercialization and commercialization activities build on our many years of industry experience in product development, sales and marketing and are designed to improve the integration of innovative new strategies into traditional product development activities," said Robert Adler, Co-Founder of Rearden Health Partners.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
